Werewolf Therapeutics

Werewolf Therapeutics is a clinical-stage biotechnology company founded in 2017 by Dan Hicklin, focused on developing a novel class of conditionally activated proinflammatory immune modulators—called WEREs (Agonists Regulated by the Environment)—that act selectively within the tumor microenvironment to treat cancer. The company's pipeline targets solid tumors and hematologic malignancies using its proprietary PREDATOR platform, which engineers cytokines and other immune-activating proteins to remain inert in healthy tissue while potently activating within tumors. Werewolf Therapeutics is publicly traded on Nasdaq under the ticker HOWL and is headquartered in the greater Boston, Massachusetts area.